Pain Relief Medication Market Segments, Size, Share, Trend, Latest Insights, Growth Rate, Future Trends and Forecast till 2032

Pain Relief Medication Market Highlights

According to MRFR analysis, The pain relief medication market size was valued at USD 93.6 billion in 2022 and is projected to grow from USD 100.3 Billion in 2023 to USD 187.78 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.2% during the forecast period (2023 - 2032).

Pain relief medicine is a branch of medicine that employs an interdisciplinary approach for easing the suffering and improving the quality of life of those living with acute as well as chronic pain.

The growth of the global pain relief medication market is driven by several factors such as increasing patient population suffering from chronic pain and cancer pain, increasing research in the pain management field, and rising product launch in the pain relief medication market. However, the stringent regulations and high cost of drugs are likely to hamper the growth of the global pain relief medication market.

Several market players currently dominate the global pain relief medication market trends. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in July 2018, AbbVie received approval for Orilissa (elagolix) from the US Food and Drug Administration (FDA) for the management of moderate to severe pain associated with endometriosis.

The global pain relief medication market continues to evolve, offering solace to millions battling discomfort. As our aging population grows and chronic pain conditions become more prevalent, this market plays a vital role in enhancing quality of life. From over-the-counter staples like ibuprofen to prescription opioids, a diverse array of options addresses varying levels of pain.

Recent years have seen a surge in non-opioid alternatives, including CBD-based products and medical cannabis, reflecting a growing demand for safer pain management. Moreover, innovative drug delivery methods, such as transdermal patches and implantable devices, are revolutionizing how pain is treated.

Segmentation

The global pain relief medication market report has been segmented based on drug class, indication, and distribution channel.

The market, based on drug class, has been divided into nonsteroidal anti-inflammatory drugs, opioids, COX-2 inhibitors, and others. The nonsteroidal anti-inflammatory drug segment is likely to be the largest during the review period due to the high efficacy rate of this drug class. The opioids segment is predicted to be the fastest-growing due to the increasing awareness about the drugs in this class in the pain relief medication market.

The global pain relief medication market has been segmented based on the indication, into cancer pain, neuropathic pain, musculoskeletal pain, inflammatory conditions, and topical foot pain relief. The cancer pain segment is expected to hold the majority share of the market owing to the increasing people suffering from this type of pain. The neuropathic pain segment is expected to be the fastest-growing due to the rising patient population in different economies.

The global pain relief medication market, by distribution channel, has been divided into hospital and retail pharmacies, and online pharmacies. The hospitals and retail pharmacies segment are projected to hold the largest share of the market due to the increasing number of hospitals in-visits. The online pharmacies segment is expected to be the fastest growing owing to the rise in the awareness about online distribution network.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East Africa. The Americas are expected to be the largest market owing to the rise in chronic diseases in this region. In Brazil, chronic pain is a widespread clinical condition, affecting between 28% and 41% of the Brazilian population. The pain relief medication market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European pain relief medication market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The pain relief medication market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rise in initiatives by public and private organizations, the market in Asia-Pacific is expected to be the fastest-growing. The pain relief medication market in the Middle East Africa has been divided into the Middle East and Africa.

Key Players

Some of the key players in the global pain relief medication market are AbbVie Inc. (US), Allergan plc (Ireland), Astellas Pharma Inc. (Japan), Bayer (Germany), Biogen Idec (US), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb (US), Eli Lilly and Company (US), GlaxoSmithKline (UK), Mallinckrodt Pharmaceuticals (UK), Pfizer, Inc. (US), Purdue Pharma (US), Sanofi (France), and Teva Pharmaceutical Industries Ltd (Israel).

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

 

Comments

Post a Comment

Popular posts from this blog

Exploring the Transformative Potential of mixed reality in healthcare market

The mixed reality in healthcare market is expected to register a CAGR of 25.04% during the forecast period of 2022 to 2030, with an estimated market value of USD 9722.85 million in 2030. The field of healthcare is constantly evolving, driven by technological advancements that seek to improve patient care, enhance medical training, and streamline clinical workflows. One such innovation making significant waves in the industry is Mixed Reality (MR). Mixed Reality combines elements of the physical and virtual worlds to create immersive and interactive experiences, and its applications in healthcare are revolutionizing the sector in myriad ways. Mixed Reality Defined Mixed Reality is a fusion of both Augmented Reality (AR) and Virtual Reality (VR). While AR overlays digital information onto the real world, VR immerses users entirely into a computer-generated environment. MR, on the other hand, seamlessly blends these two experiences, allowing users to interact with virtual objects w...
Read more

Insulin Biosimilars Market Report, Key Trends, Competitive Scenario, Current and Future Players 2032

Insulin Biosimilars Market Highlights A disease in which the body’s ability to produce or respond to the hormone insulin is impaired, resulting in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood is termed diabetes. Biosimilar insulin is designed to be highly like the original, or reference, insulin product described in a patent. As patents for major branded insulin products start to expire, several biosimilar insulin markets are expected to launch in the coming years. According to MRFR analysis, Insulin Biosimilars Market size is expected to reach USD 1.68 billion by 2032 at a CAGR of 14.6% during the forecast period of 2023 to 2032. The USFDA approved new insulin glargine Basilar, for type 1 and type 2 diabetes which is a biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim’s biosimilar insulin glargine has got approval through the European Medicines Agency’s (EMA’s) Biosimilar p...
Read more

Leuprolide Acetate Market Share, Analysis and Projection, Region - Global Forecast to 2030

Market Scenario The leuprolide acetate market size is projected to reach USD 2,400 Million by 2030 at 10.50% CAGR during the forecast period 2022-2030. Leuprolide acetate is a medication used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, and early puberty . The medication works by decreasing testosterone levels in men and estrogen levels in women . The report states that the increasing prevalence of prostate cancer and endometriosis is expected to drive the growth of the leuprolide acetate market in the projected timeframe . The report also highlights that side effects such as hot flashes, night sweats, decreased libido, erectile dysfunction, and osteoporosis associated with leuprolide acetate treatment are some factors which will likely act as market restraints for the growth of the leuprolide acetate market in the above mentioned projected timeframe . Key Players: GPI Golrang pharmaceutical investment (Russia), Bachem(Switzerland), avenit AG (...
Read more